Tarsus Pharmaceuticals, Inc. — Form 4
Filed September 9, 2026 · analyzed by the Insider Agent
4
▼ Likely negative
significance 39/100
What the filing says
President/CEO and Board Chair Azamian Bobak R. (TARS) sold 10K shares (~$906K) on the open market (1.2% of holdings). Open-market sale — often routine.
Why this rating
Open-market sale — often routine.
See more from September 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.